Company: MLTX
Filing Date: 2025-11-05
Form Type: 8-K
Source: 0001821586-25-000021
Chunk: 1

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01. Regulation FD Disclosure.

On November 5, 2025, the Company issued a press release announcing results from its Phase 2 clinical trial of Sonelokimab (“ SLK”) in adult patients with palmoplantar pustulosis (the “ LEDA” trial), as well as an interim analysis of its Phase 3 clinical trial of SLK in adolescents with hidradenitis suppurativa (the “ VELA-TEEN” trial). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This Item 7.01 and the press release attached hereto as Exhibit 99.1, are being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.